NASDAQ:ITCI - Intra-Cellular Therapies Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$20.40 -0.04 (-0.20 %)
(As of 07/16/2018 04:00 PM ET)
Previous Close$20.44
Today's Range$20.11 - $20.48
52-Week Range$10.25 - $25.82
Volume119,000 shs
Average Volume455,027 shs
Market Capitalization$1.12 billion
P/E Ratio-9.62
Dividend YieldN/A
Beta0.75
Intra-Cellular Therapies logoIntra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. It is also developing ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.

Receive ITCI News and Ratings via Email

Sign-up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ITCI
CUSIPN/A
Phone646-440-9333

Debt

Debt-to-Equity RatioN/A
Current Ratio22.55
Quick Ratio22.55

Price-To-Earnings

Trailing P/E Ratio-9.62
Forward P/E Ratio-6.05
P/E GrowthN/A

Sales & Book Value

Annual Sales$250,000.00
Price / Sales4,463.52
Cash FlowN/A
Price / CashN/A
Book Value$8.33 per share
Price / Book2.45

Profitability

EPS (Most Recent Fiscal Year)($2.12)
Net Income$-97,770,000.00
Net Margins-39,745.53%
Return on Equity-27.67%
Return on Assets-26.57%

Miscellaneous

Employees49
Outstanding Shares54,700,000
Market Cap$1,117.99

The Truth About Cryptocurrencies

Intra-Cellular Therapies (NASDAQ:ITCI) Frequently Asked Questions

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies Inc (NASDAQ:ITCI) issued its earnings results on Thursday, May, 3rd. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.66) by $0.01. Intra-Cellular Therapies had a negative net margin of 39,745.53% and a negative return on equity of 27.67%. View Intra-Cellular Therapies' Earnings History.

When is Intra-Cellular Therapies' next earnings date?

Intra-Cellular Therapies is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Intra-Cellular Therapies.

What price target have analysts set for ITCI?

10 equities research analysts have issued 12 month price objectives for Intra-Cellular Therapies' stock. Their predictions range from $24.00 to $36.00. On average, they expect Intra-Cellular Therapies' share price to reach $29.10 in the next twelve months. This suggests a possible upside of 42.6% from the stock's current price. View Analyst Ratings for Intra-Cellular Therapies.

What is the consensus analysts' recommendation for Intra-Cellular Therapies?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Intra-Cellular Therapies stock?

Here are some recent quotes from research analysts about Intra-Cellular Therapies stock:
  • 1. According to Zacks Investment Research, "Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York. " (5/8/2018)
  • 2. Cantor Fitzgerald analysts commented, "Lumateperone NDA filing still expected in mid-2018. We view the pre- NDA meeting (and what may be said thereafter), the actual filing and the FDA acceptance of it (presumably) as minor events that are expected and not stock moving." (3/1/2018)
  • 3. SunTrust Banks, Inc. analysts commented, "Meeting with FDA could help identify the path forward for ralinepag. On the 3Q17 results conference call, management commented that the company will seek a meeting with the FDA to determine the pivotal development plan for ralinepag. Specific timing of the meeting is pending FDA scheduling but management laid out their views on the drug candidate’s development program. Key considerations include 1) accelerating time to market, 2) maximizing the breadth and scope of label, 3) raising physician awareness of the compound and 4) comparing ralinepag with other available treatments." (11/8/2017)

Who are some of Intra-Cellular Therapies' key competitors?

Who are Intra-Cellular Therapies' key executives?

Intra-Cellular Therapies' management team includes the folowing people:
  • Dr. Sharon Mates Ph.D., Co-Founder, Chairman, CEO & Pres (Age 65)
  • Mr. Lawrence J. Hineline CPA, VP of Fin., CFO, Treasurer & Assistant Sec. (Age 62)
  • Dr. Robert E. Davis Ph.D., Sr. VP & Chief Scientific Officer (Age 67)
  • Mr. Michael I. Halstead J.D., Sr. VP, Gen. Counsel, Corp. Compliance Officer & Sec. (Age 45)
  • Dr. Kimberly E. Vanover Ph.D., Sr. VP of Clinical Devel. (Age 52)

Has Intra-Cellular Therapies been receiving favorable news coverage?

Press coverage about ITCI stock has trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Intra-Cellular Therapies earned a media sentiment score of 0.19 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 44.74 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intra-Cellular Therapies' stock price today?

One share of ITCI stock can currently be purchased for approximately $20.40.

How big of a company is Intra-Cellular Therapies?

Intra-Cellular Therapies has a market capitalization of $1.12 billion and generates $250,000.00 in revenue each year. The biopharmaceutical company earns $-97,770,000.00 in net income (profit) each year or ($2.12) on an earnings per share basis. Intra-Cellular Therapies employs 49 workers across the globe.

How can I contact Intra-Cellular Therapies?

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected]


MarketBeat Community Rating for Intra-Cellular Therapies (NASDAQ ITCI)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  306 (Vote Outperform)
Underperform Votes:  206 (Vote Underperform)
Total Votes:  512
MarketBeat's community ratings are surveys of what our community members think about Intra-Cellular Therapies and other stocks. Vote "Outperform" if you believe ITCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ITCI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.